PATENT
Docket No. 265.00260101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Watowich et al.	Group Art Unit:	1632
Serial No.:	09/981,286	Examiner:	Unknown
Confirmation No.:	4993		
Filed:	October 15, 2001		
For:	DRUG DISCOVERY METHODS		

**PRELIMINARY AMENDMENT,
COMMUNICATION REGARDING ENTRY OF SEQUENCE LISTING,
AND PROPOSED DRAWING CORRECTIONS**

Assistant Commissioner for Patents
ATTN: Missing Parts
Washington, D.C. 20231

Dear Sir:

Prior to taking up the above-identified application for examination, please amend the application as follows:

In the Specification

Please replace the paragraph beginning at page 20, line 20, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

The tat-CCD construct was produced by PCR using CCD in the pET30 vector and the primers N-TATCCD (5'ATGTACGGTCGTAAAAAACGTCGTCAGCGTCGTCGTGTCATGAAATTGGAATCTG ACA3' SEQ ID NO:35) and CBAM-VEE (5'GAATTCGGATCCTCATTACCATTGCTCGCAGTTCTCCGGAGT3' SEQ ID NO:36). The PCR product was phenol-chloroform extracted and was ligated into the pETBLUE vector. It was then transformed into NovaBlue Singles (Novagen) and plated on LB-Bluogal-IPTG-

carbenicillin-tetracycline plates. White colonies were selected for amplification, plasmid purification, and sequencing. The tat-CCD cDNA sequence was determined and is depicted in Figure 3.

Please replace the paragraph beginning at page 26, line 28, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

Additional approaches to constructing the insert containing the library are also being used. One of these approaches involves annealing a negative strand of LIB (termed LIB r/c) to LIB itself. The LIB r/c sequence was (5'TCGAGGGAACCACC(MNN)mACCACCGGAG (SEQ ID NO:25)), where M= C, A. When LIB and LIB r/c were annealed, cohesive ends for BamHI and XhoI are formed. Another approach is to use Sequenase V 2.0 (USB, Cleveland, Ohio) to synthesize the negative LIB strand. The oligos for this are LIBSEQBAM (5'GCACGGATCCTCCGGTGGT(NNK)mGGTGGTTCCCTCGAGATCG (SEQ ID NO:26)) and SEQBAM Rev (5'CGATCTCGAGGGAACCATC (SEQ ID NO:27)). This sequenase product is then digested with BamHI (Promega, Madison, WI), and XhoI for insertion into the tat-CCD:BAM expression vectors.

SEQUENCE LISTING

In accordance with 37 C.F.R. §1.821 et seq., a computer readable form (CRF) and written Sequence Listing for the above-captioned application are submitted herewith. Applicants request entry of same into the specification.

In accordance with 37 C.F.R. §1.821 et seq., it is respectfully submitted that the written Sequence Listing and the Computer readable form of the Sequence Listing are identical. It is further submitted that Sequence Listing does not contain new matter.

CORRECTION OF DRAWINGS

Applicants submit herewith proposed corrected drawings to replace originally filed sheets 3 and 4, which contain Figures 2B and 2C. The proposed corrections identify the sequences contained therein with the assigned SEQ ID NO. Additionally, at the bottom of Figure 2B, on the left hand side, text has inadvertently been omitted. Support for these corrections is found in SEQ ID NOS: 31, 32 and 12 of Figures 1 and 2A as originally filed. These changes are shown in red on the proposed corrected drawings submitted herewith. Approval of the proposed corrected drawings is respectfully requested.

Remarks

The specification is amended to identify two nucleic acid sequences with SEQ ID NOs. The specification is also amended to correct a typographical error and is supported by the specification at, for instance, page 11, lines 18-28.

The drawings are amended to identify SEQ ID NOs., and to correct inadvertently omitted text.

Conclusion

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if there are any questions regarding this Preliminary Amendment or if prosecution of this application may be assisted thereby.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Attn: Missing Parts, Washington, D.C. 20231, on this 28th day of January, 2002.

David L Provence

David L. Provence

January 28, 2002
Date

Respectfully submitted,

Watowich et al.

By
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Telephone: (612) 305-1220
Facsimile: (612) 305-1228

By: David L Provence

David L. Provence
Reg. No. 43,022
Direct Dial (612) 305-1005

APPENDIX A - SPECIFICATION/CLAIM AMENDMENTS INCLUDING NOTATIONS TO INDICATE CHANGES MADE
Serial No.: 09/981,286
Docket No. 265.00260101

Amendments to the following are indicated by underlining what has been added and bracketing what has been deleted. Additionally, all amendments have been shaded.

In the Specification

The paragraph beginning at page 20, line 20, has been amended as follows:

The tat-CCD construct was produced by PCR using CCD in the pET30 vector and the primers N-TATCCD (5'ATGTACGGTCGTAAAAAACGTCGTCAGCGTCGTCGTGTCATGAAATTGGAATCTG ACA3' SEQ ID NO:35) and CBAM-VEE (5'GAATTCGGATCCTCATTACCATTGCTCGCAGTTCTCCGGAGT3' SEQ ID NO:36). The PCR product was phenol-chloroform extracted and was ligated into the pETBLUE vector. It was then transformed into NovaBlue Singles (Novagen) and plated on LB-Bluogal-IPTG-carbenicillin-tetracycline plates. White colonies were selected for amplification, plasmid purification, and sequencing. The tat-CCD cDNA sequence was determined and is depicted in Figure 3.

The paragraph beginning at page 26, line 28, has been amended as follows:

Additional approaches to constructing the insert containing the library are also being used. One of these approaches involves annealing a negative strand of LIB (termed LIB r/c) to LIB itself. The LIB r/c sequence was (5'TCGAGGGAACCACC(MNN)mACCACCGGAG (SEQ ID NO:25)), where M= C, A. When LIB and LIB r/c were annealed, cohesive ends for BamHI and XhoI are formed. Another approach is to use Sequenase V 2.0 (USB, Cleveland, Ohio) to synthesize the negative LIB strand. The oligos for this are LIBSEQBAM (5'GCACGGATCCTCCGGTGGT(NNK)m[o]GGTGGTTCCCTCGAGATCG (SEQ ID NO:26)) and SEQBAM Rev (5'CGATCTCGAGGGAACCATC (SEQ ID NO:27)). This sequenase product is then digested with BamHI (Promega, Madison, WI), and XhoI for insertion into the tat-CCD:BAM expression vectors.

Alignment of adaptein nucleotide sequences with CCD sequence:

SEQ ID NO: 31 A-1 GTCATGAAAT TGGAATCTGA CAAGACGTTC CCAATCATGT TGGAAGGGAA
SEQ ID NO: 32 A-2 GTCATGAAAT TGGAATCTGA CAAGACGTTC CCAATCATGT TGGAAGGGAA
SEQ ID NO: 12 CCD GTCATGAAAT TGGAATCTGA CAAGACGTTC CCAATCATGT TGGAAGGGAA

A-1 GATAAACGGC TACGCTTGTG TGGTCGGAGG GAAGTTATTC AGGCCGATGC
A-2 GATAAACGGC TACGCTTGTG TGGTCGGAGG GAAGTTATTC AGGCCGATGC
CCD GATAAACGGC TACGCTTGTG TGGTCGGAGG GAAGTTATTC AGGCCGATGC

A-1 ATGTGGAAGG CAAGATCGAC AACGACGTTC TGGCCGCGCT TAAGACGAAG
A-2 ATGTGGAAGG CAAGATCGAC AACGACGTTC TGGCCGCGCT TAAGACGAAG
CCD ATGTGGAAGG CAAGATCGAC AACGACGTTC TGGCCGCGCT TAAGACGAAG

A-1 AAAGCATCCA AATACGATCT TGAGTATGCA GATGTGCCAC AGAACATGCG
A-2 AAAGCATCCA AATACGATCT TGAGTATGCA GATGTGCCAC AGAACATGCG
CCD AAAGCATCCA AATACGATCT TGAGTATGCA GATGTGCCAC AGAACATGCG

A-1 GGCCGATACA TTCAAATACA CCCATGAGAA ACCCCAAGGC TATTACAGCT
A-2 GGCCGATACA TTCAAATACA CCCATGAGAA ACCCCAAGGC TATTACAGCT
CCD GGCCGATACA TTCAAATACA CCCATGAGAA ACCCCAAGGC TATTACAGCT

A-1 GGCATCATGG AGCAGTCCAA TATGAAAATG GGCGTTTCAC GGTGCCGAAA
A-2 GGCATCATGG AGCAGTCCAA TATGAAAATG GGCGTTTCAC GGTGCCGAAA
CCD GGCATCATGG AGCAGTCCAA TATGAAAATG GGCGTTTCAC GGTGCCGAAA

A-1 GGAGTTGGGG CCAAGGGAGA CAGCGGACGA CCCATTCTGG ATAACCAGGG
A-2 GGAGTTGGGG CCAAGGGAGA CAGCGGACGA CCCATTCTGG ATAACCAGGG
CCD GGAGTTGGGG CCAAGGGAGA CAGCGGACGA CCCATTCTGG ATAACCAGGG

A-1 AGGGGTGGTC GCTATTGTGC TGGGAGGTGT GAATGAAGGA TCTAGGACAG
A-2 AGGGGTGGTC GCTATTGTGC TGGGAGGTGT GAATGAAGGA TCTAGGACAG
CCD AGGGGTGGTC GCTATTGTGC TGGGAGGTGT GAATGAAGGA TCTAGGACAG

(HindIII) (XhoI)
A-1 CCCTTTCAGT CGTCATGTGG AAC---AAGCTT TCTCCACATTA TGCTCAA CTCGAG
A-2 CCCTTTCAGT CGTCATGTGG AAC---AAGCTT AGAAGCGGTAC TCAATGG CTCGAG
CCD CCCTTTCAGT CGTCATGTGG AACGAG------- ---------- ------- ------

A-1 ---GGAGTTA CCGTGAAGTA TACTCCGGAG AACTGCGAGC AATGGTAATGAGC
A-2 ---GGAGTTA CCGTGAAGTA TACTCCGGAG AACTGCGAGC AATGGTAATGAGC
CCD AAGGGAGTTA CCGTGAAGTA TACTCCGGAG AACTGCGAGC AATGGTAATGAGC

Figure 2B

Figure 2C

Alignment of adaptein protein sequences with CCD sequence:

SEQ ID NO:33	A-1	VMKLESDKTF PIMLEGKING YACVVGGKLF RPMHVEGKID NDVLAALKTK
SEQ ID NO:34	A-2	VMKLESDKTF PIMLEGKING YACVVGGKLF RPMHVEGKID NDVLAALKTK
SEQ ID NO:1	CCD	VMKLESDKTF PIMLEGKING YACVVGGKLF RPMHVEGKID NDVLAALKTK
	A-1	KASKYDLEYA DVPQNMRADT FKYTHEKPQG YYSWHHGAVQ YENGRFTVPK
	A-2	KASKYDLEYA DVPQNMRADT FKYTHEKPQG YYSWHHGAVQ YENGRFTVPK
	CCD	KASKYDLEYA DVPQNMRADT FKYTHEKPQG YYSWHHGAVQ YENGRFTVPK
	A-1	GVGAKGDSGR PILDNQGRVV AIVLGGVNEG SRTALSVVMW N-KLSPHYAQLE
	A-2	GVGAKGDSGR PILDNQGRVV AIVLGGVNEG SRTALSVVMW N-KLRSGTQWLE
	CCD	GVGAKGDSGR PILDNQGRVV AIVLGGVNEG SRTALSVVMW NE----------
	A-1	-GVTVKYTPE NCEQW
	A-2	-GVTVKYTPE NCEQW
	CCD	KGVTVKYTPE NCEQW